 |
|
|
|
|
|
|
|
 |
 |
|
|
|
Telomelysin® is a therapeutic modality derived from adenovirus. Telomelysin® is generated by replacing the normal transcriptional regulatory element of the E1A gene in the human adenovirus type 5 with the human telomerase reverse transcriptase (hTERT) promoter. Telomerase is an enzyme expressed in approximately 90% of all types of cancer cells. The hTERT promoter is the key for the expression of telomerase, as well as for the complete replication of chromosomal ends. Telomelysin® is able to achieve a high replication rate, due to the internal ribosome entry site (IRES) gene inserted between the E1A and E1Bgenes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Copyright
(c)2004-2005, Oncolys BioPharma Inc. All rights reserved.
|
|
